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Abstract: Sarcomas are rare cancers with a spectrum of clinical needs and outcomes. We investigated
care experiences and health-related quality of life (HRQoL) in sarcoma patients during the COVID-19
pandemic. Patients with appointments during the first two months of the UK lockdown were
invited to complete a survey. Questions included views on care modifications, COVID-19 worry and
psychosocial impact, and EORTC-QLQ-C30 items. 350 patients completed the survey; median age 58
(16–92) years. Care modifications included telemedicine (74%) and postponement of appointments
(34%), scans (34%) or treatment (10%). Most felt the quality of care was not affected (72%), however,
social life (87%) and emotional wellbeing (41%) were affected. Worry about COVID-19 infection was
moderately high (mean 5.8/10) and significantly related to higher cancer-related worry; associated
with lower emotional functioning irrespective of treatment intent. Curative patients (44%) with
low resilient coping scores had significantly higher COVID-19 worry. Patients who did not know
their treatment intent (22%) had significantly higher COVID-19 worry and insomnia. In summary,
care experiences were generally positive; however, cancer-related worry, low resilient coping and
uncertainty about treatment intent were associated with COVID-19 worry. These patients may benefit
from additional psychological support during the pandemic and beyond.
Keywords: sarcomas; HRQoL; COVID-19; patient experience
1. Introduction
The current COVID-19 pandemic caused by a novel betacoronavirus (SARS-CoV-2) is a global
health emergency [1,2]. As of 1 June 2020, there have been nearly 6 million confirmed cases and over
350,000 deaths across the world [2]. Mitigation and containment measures, including social distancing
and quarantine, have been widely implemented in attempts to delay transmission and reduce the
number of fatalities [3,4]. On 23 March 2020, the government of the United Kingdom (UK) announced
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a national policy mandating the entire country to stay at home except for very limited purposes such
as medical need or employment in key professions [5].
Although the majority of people with COVID-19 infection will have mild–moderate symptoms
(80%), the exponential rise in cases precipitated an unprecedented impact on international healthcare
systems [6]. Up to 40% of hospitalised patients will require respiratory support and around 6% require
mechanical ventilation [7–9]. Mortality rates are estimated to be between 1–4% [10]. Risk factors for
death include older age, Asian and Black ethnic origin, and pre-existing medical conditions such as
diabetes, hypertension, coronary artery disease and obesity [1,11]. Patients with cancer may also be
more susceptible to COVID-19 and complications due to pulmonary disease, immune compromise
caused by malignancy or anti-cancer treatments, and exposure to the virus through frequent visits to
healthcare facilities [12]. Early data from China demonstrated that patients with cancer had a higher
mortality rate, compared to patients without cancer [13]. These findings have been supported by more
recent data from Europe and the United States [14–16]. It was therefore deemed critical to implement
effective, primary preventive measures to reduce exposure and minimise risk for patients with cancer.
On 20 March 2020, the National Institute for Clinical Excellence (NICE) published guidelines
for the delivery of cancer care in the UK during the COVID-19 pandemic [17]. Recommendations
included postponing non-essential procedures, selective conversion of appointments to telemedicine,
and prioritising patients for systemic treatment [17]. Although the impact of modifications on patients
with cancer has not been described, it is widely acknowledged that the pandemic has had a negative
impact on mental health and wellbeing in the general population [18–21].
Sarcomas are rare, heterogeneous cancers of mesenchymal origin that can arise in patients of any
age. Prognosis is widely variable and is related to factors such as histological subtype and disease
stage. Due to the wide spectrum of clinical need and outcomes for these patients, this is a unique and
relevant group of patients to study during the COVID-19 pandemic, representing a microcosm of all
solid cancers. The primary aims of this study were to assess the impact of the COVID-19 pandemic on
care experiences, worry and health-related quality of life (HRQoL) in patients with sarcomas.
2. Results
2.1. Patient Characteristics
Three hundred and fifty patients participated in the survey (response rate: 44%; Appendix A).
The median age of patients was 58 (range 16–92) years, with a slightly higher proportion of females
(n = 192, 55%) (Table 1). The majority were of Caucasian/European ethnic origin (n = 286, 82%) and
were well-educated (college/diploma/vocational qualification or higher) (n = 255, 73%). Most patients
were living with others (n = 303, 87%) and had a partner (n = 245, 70%). Co-morbidities associated with
poor COVID-19 outcomes were infrequent; most common was hypertension (n = 76, 22%). The majority
of patients usually travelled more than one hour to reach their sarcoma centre (n = 243, 70%).
Table 1. Participant characteristics.
Patient Characteristics
All Participants
(n = 350)
n (%)
Curative Intent
(n = 150)
n (%)
Palliative Intent
(n = 117)
n (%)
Intent Unknown
(n = 77)
n (%)
p-Value
Age (years)
Mean 56.1 52.0 61.4 56.3
0.060(SD) (17.3) (17.9) (14.6) (17.8)
Gender
Male 158 (45) 65 (43) 58 (50) 31 (30)
0.394Female 192 (55) 85 (57) 59 (50) 46 (60)
Ethnicity
Caucasian/European 286 (82) 121 (81) 100 (87) 59 (77)
0.168Other 62 (18) 29 (19) 15 (13) 18 (23)
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Table 1. Cont.
Patient Characteristics
All Participants
(n = 350)
n (%)
Curative Intent
(n = 150)
n (%)
Palliative Intent
(n = 117)
n (%)
Intent Unknown
(n = 77)
n (%)
p-Value
Living situation
Alone 47 (13) 16 (11) 18 (15) 12 (16)
0.439Cohabiting 303 (87) 134 (89) 99 (85) 65 (84)
Marital status
Partner 245 (70) 115 (77) 81 (69) 45 (58)
0.017No partner 105 (30) 35 (23) 36 (31) 32 (42)
Education level
Low 94 (27) 35 (23) 28 (24) 28 (36)
0.081Medium 114 (33) 48 (32) 37 (32) 28 (36)
High 141 (40) 67 (45) 51 (44) 21 (27)
Loneliness
Not lonely 85 (24) 120 (80) 89 (76) 52 (68)
0.115Lonely 265 (76) 30 (20) 28 (24) 25 (32)
Resilient coping
Low 115 (33) 51 (34) 30 (26) 32 (42)
0.066Medium 161 (46) 73 (49) 60 (51) 26 (34)
High 74 (21) 26 (17) 27 (23) 19 (25)
Comorbidities
COPD 9 (3) 2 (1) 5 (4) 2 (3) 0.380
Hypertension 76 (22) 28 (19) 30 (26) 17 (22) 0.388
Diabetes 29 (8) 7 (5) 12 (10) 10 (13) 0.061
Coronary artery disease 17 (5) 5 (3) 10 (9) 1 (1) 0.055
Obesity 31 (9) 10 (7) 9 (8) 12 (16) 0.085
None of above 232 (66) 110 (73) 68 (58) 49 (64) 0.030
Journey to hospital > 1 h 243 (70) 93 (62) 90 (77) 57 (77) 0.014
Transport to hospital ≥ 2 modes 165 (47) 69 (46) 62 (53) 30 (39) 0.152
Cancer items
Current treatment
IV chemotherapy 38 (11) 11 (7) 24 (21) 3 (4)
0.0001
Oral chemotherapy/TKI 66 (19) 14 (9) 42 (36) 10 (13)
Radiotherapy 13 (4) 6 (4) 6 (5) 1 (1)
Other treatment 10 (3) 3 (2) 3 (3) 1 (1)
No treatment 218 (63) 113 (76) 41 (35) 59 (77)
Clinical trial
Yes 29 (8) 6 (4) 19 (16) 4 (5) 0.001
Follow-up frequency
Less than 3 monthly 93 (27) 25 (17) 48 (41) 19 (25)
0.0001
3–4 monthly 148 (43) 61 (41) 48 (41) 34 (44)
6 monthly 47 (14) 29 (20) 9 (8) 9 (12)
Annual 23 (7) 19 (13) 2 (2) 2 (3)
Other 37 (11) 14 (10) 10 (9) 13 (17)
2.2. Loneliness
Around half the patients felt isolated; 130 patients (37%) felt isolated some of the time and 78
(11%) often felt isolated. Overall, 85 patients (24%) were lonely and 265 patients were not lonely
(76%). Loneliness was associated with younger age; adolescents and young adults (aged 16–39 years;
33%), middle-aged (aged 40–64; 29%), elderly (aged ≥ 65 years; 15%); p = 0.004. Loneliness was
also more common in patients who were not of Caucasian/European ethnic origin (36% vs. 22%
Caucasian/European; p = 0.021), patients who were living alone (51% vs. 20% cohabiting; p = 0.0001),
and those without a partner (41% vs. 17% with partner; p = 0.0001).
2.3. Resilient Coping
Participants had a mean resilient coping score of 14.6 (SD = 2.7) suggesting most participants were
low to medium resilient copers. One hundred and fifteen patients (33%) scored less than 14 points
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(low resilient copers), 161 patients (46%) scored between 14 and 16 points (medium resilient copers)
and 74 patients (21%) were high resilient copers.
2.4. Treatment Characteristics
The majority of patients reported that the intent of their treatment or management plan was
curative/no evidence of disease (n = 150, 44%) or palliative (n = 117, 34%), however, 77 patients
(22%) did not know their treatment intent (unknown intent). One hundred and twenty-seven patients
(36%) were currently receiving treatment for sarcoma; intravenous chemotherapy (n = 38, 11%),
oral anti-cancer treatments (n = 66, 19%), radiotherapy (n = 13, 4%) and other treatments such as
microwave ablation (n = 10, 3%). Twenty-nine patients (8%) were taking part in a clinical trial.
2.5. COVID-19: Worry and Psychosocial Impact
Mean overall level of worry about the impact of COVID-19 on personal health was 5.8 out of 10
(standard deviation {SD} 2.5). Of all respondents, patients who did not know their treatment intent
were the most worried about COVID-19 (6.5/10) compared to patients with palliative intent (6.0/10)
or curative intent (5.4/10) treatment (p = 0.004). Mean level of worry about sarcoma was 5.5/10 (SD
2.6) and was highest among patients treated with palliative intent. Figure 1 demonstrates the mean
level of worry about COVID-19 and sarcoma according to treatment intent and current treatment
status (on active treatment versus not on treatment). In patients treated with curative intent, patients
on active treatment were significantly more worried about sarcoma (p = 0.016) and about COVID-19
(p = 0.040) compared to curative patients who were not on active treatment. Patients who did not
know their treatment intent (unknown group) and were on active treatment were also significantly
more worried about COVID-19 (p = 0.005) and were more worried about sarcoma than those not on
treatment, although this did not reach statistical significance (p = 0.054). Treatment status in palliative
patients was not associated with sarcoma worry or COVID-19 worry.
Figure 1. Sarcoma and COVID-19 worry according to treatment intent and active treatment status.
* p < 0.05.
Cancers 2020, 12, 2288 5 of 26
Around half the patients thought that they were at a higher risk of COVID-19 than the general
population (n = 167, 48%) (Table 2). Patients with co-morbidities associated with poor COVID-19
outcomes (56% vs. 44% no comorbidities; p = 0.049), who were lonely (62% vs. 38% not lonely;
p = 0.002) or on treatment (60% vs. 40%; p = 0.001) were more likely to report a higher perceived risk
of COVID-19. No participants had confirmed COVID-19 infection. Of the 40 patients (11%) reporting
symptoms of COVID-19, six patients tested negative (2%) while others were not tested. The COVID-19
pandemic impacted finances (n = 84, 24%), employment (n = 86, 25%), emotional wellbeing (n = 145,
41%), family life (n = 210, 60%) and social life/activities (n = 306, 87%). The majority of patients
(n = 255, 73%) indicated that they would accept ventilation in the event of a potentially life-threatening
respiratory disease, however, a considerable proportion were not sure (n = 75, 22%).
Table 2. COVID-19 items.
COVID-19 Items Alln (%)
Curative Intent
n (%)
Palliative Intent
n (%)
Intent Unknown
n (%) p-Value
Perceived risk vs.
Population
Higher 167 (48) 52 (35) 70 (60) 44 (57)
0.0001
Equal 135 (39) 77 (51) 30 (26) 26 (34)
Lower 30 (9) 14 (9) 13 (11) 1 (1)
Do not know 18 (5) 7 (5) 4 (3) 6 (8)
COVID-19 symptoms/test
Symptoms, negative test 6 (2) 5 (3) 1 (1) 0 (0)
0.150
Symptoms, no test 34 (10) 15 (10) 13 (11) 6 (8)
No symptoms 265 (76) 113 (75) 91 (78) 55 (71)
Do not know 45 (13) 17 (11) 12 (10) 16 (21)
COVID-19 pandemic impact
Employment 86 (25) 37 (25) 32 (27) 15 (20) 0.459
Financial situation 84 (24) 33 (22) 29 (25) 21 (27) 0.661
Family life 210 (60) 85 (57) 79 (68) 42 (55) 0.112
Emotional wellbeing 145 (41) 62 (41) 48 (41) 33 (43) 0.979
Social life/activities 306 (87) 130 (87) 103 (88) 67 (87) 0.978
Would accept ventilator
Yes 255 (73) 119 (79) 82 (70) 50 (65)
0.175No 19 (5) 6 (4) 8 (7) 5 (7)
Do not know 75 (22) 25 (17) 27 (23) 22 (29)
2.6. Experiences of Care during COVID-19 Pandemic
A large proportion of patients who reported having an appointment (n = 286, 82%) had a
telemedicine consultation (telephone/video) (n = 211, 74%) (Table 3). Satisfaction with telemedicine
was generally high; telephone appointment mean score 8.7/10 (SD 1.7), video appointment mean score
7.4/10 (SD 3.4). Satisfaction with face to face appointments was also high 8.4/10 (SD 2.6). Nearly
three-quarters of patients (n = 259, 74%) indicated preference for some telemedicine appointments in
the future, however, 78 patients (22%) would prefer face to face appointments only. Resilient coping
level (p = 0.024) and treatment intent (p = 0.047) were significantly associated with preference for face
to face appointments only; patients with a low resilient coping score, and those who were uncertain
about their treatment intent were most likely to prefer face to face appointments. Most participants
who preferred face to face appointments indicated it was more reassuring (n = 58, 74%). Preference
for some telemedicine appointments was due to reduced travel time (n = 121, n = 47%), cost of travel
(n = 60, 23%), or convenience (n = 89, 34%). Patient characteristics (e.g., age), treatment intent and
journey time to hospital were not associated with appointment preferences.
Around one third of patients had their follow-up appointments (n = 117, 34%) or scans (n = 106,
31%) postponed by at least three months (Table 3). Patient age was associated with postponement of
appointments (p = 0.016); patients aged≥65 years were the most likely to have postponed appointments
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(43%). Treatment was paused or discontinued for a minority of patients (n = 34, 10%). Six patients
reported that trial participation had been paused due to the pandemic. A further nine patients were
being considered for trial enrolment, but participation was put on hold due to the pandemic.
Postponement of treatment was significantly associated with treatment intent (p = 0.0001);
most common among patients treated with palliative intent (Table 3). Patients generally indicated that
postponement of appointments and scans were good decisions (70% and 59%, respectively). Patients
treated with palliative intent were significantly more likely to be unsure whether postponement of
treatment was a good or bad decision (neutral) compared to those treated with curative or unknown
intent (p = 0.032).
Participants were most likely to contact their sarcoma clinical nurse specialist (n = 272, 78%) or the
Royal Marsden National Health Service (NHS) Foundation Trust (RMH) or University College London
Hospitals NHS Foundation Trust (UCLH) helpline (n = 179, 51%) in cases of cancer-related concerns.
Almost two-thirds of participants felt able to contact the healthcare team as normal (n = 223, 64%),
however, a substantial number indicated that they would only contact their team in an emergency
situation (n = 95, 27%).
Table 3. Patient reported experiences of care.
Experiences of Care AllParticipants
Curative
Intent
Palliative
Intent
Intent
Unknown p-Value
Appointment type
Face to face appointment 75 (26) 32 (27) 35 (33) 8 (14)
0.003Telemedicine appointment 211 (74) 86 (73) 70 (67) 51 (86)
Preferred appointment type
Face to face (F2F) only * 78 (22) 29 (19) 25 (22) 23 (30)
0.047
Mostly F2F, occasional telemedicine 129 (37) 68 (45) 36 (31) 23 (30)
Mostly telemedicine, occasional F2F 118 (34) 44 (29) 48 (41) 23 (30)
Only telemedicine 12 (4) 6 (4) 4 (3) 2 (3)
Unsure 12 (4) 3 (2) 3 (3) 6 (8)
Appointment modification
Postponed 117 (34) 48 (33) 40 (35) 28 (36) 0.853
Opinion on postponement
Positive 82 (70) 39 (81) 24 (60) 18 (64)
0.220Negative 10 (9) 2 (4) 4 (10) 4 (14)
Neutral 24 (21) 7 (15) 11 (28) 6 (21)
Imaging modification
Postponed 106 (31) 42 (29) 33 (30) 28 (37) 0.422
Opinion on postponement
Positive 63 (59) 28 (67) 18 (55) 14 (50)
0.212Negative 11 (10) 2 (5) 3 (9) 6 (21)
Neutral 32 (30) 12 (29) 12 (36) 8 (29)
Treatment modification
Postponed 29 (9) 5 (3) 20 (18) 4 (5)
0.0001Discontinued 5 (2) 2 (1) 3 (3) 0 (0)
Opinion on postponed/stopped
Positive 14 (48) 3 (75) 8 (40) 3 (75)
0.093Negative 2 (7) 1 (25) 1 (5) 0 (0)
Neutral 12 (41) 0 (0) 11 (55) 1 (25)
Impact of pandemic on care quality
Positive 4 (1) 3 (2) 0 (0) 1 (1)
0.155
Negative 50 (15) 18 (12) 23 (20) 8 (10)
Not affected 250 (72) 113 (76) 78 (68) 55 (71)
Unsure 42 (12) 14 (10) 14 (12) 13 (17)
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Table 3. Cont.
Experiences of Care AllParticipants
Curative
Intent
Palliative
Intent
Intent
Unknown p-Value
Informed about care plan
Very well informed 190 (55) 94 (63) 57 (49) 35 (47)
0.017
Informed 126 (36) 44 (30) 53 (45) 27 (36)
Little information 23 (7) 8 (5) 5 (4) 10 (13)
Not informed 8 (2) 3 (2) 2 (2) 3 (4)
Contacting HCP during pandemic **
Contact as normal 223 (64) 98 (66) 79 (68) 44 (57)
0.019
Worried about availability 19 (5) 6 (4) 10 (9) 2 (3)
Only if essential 95 (27) 39 (26) 28 (24) 25 (33)
Do not know 12 (3) 6 (4) 0 (0) 6 (8)
Contact for cancer support
Clinical nurse specialist 272 (78) 114 (76) 96 (82) 60 (78) 0.482
Sarcoma helpline (RMH/UCLH) 179 (51) 80 (53) 61 (52) 33 (43) 0.300
General practitioner (GP) 72 (21) 29 (19) 22 (19) 29 (26) 0.420
NHS helpline 15 (4) 5 (3) 4 (3) 5 (7) 0.474
Sarcoma charity 19 (5) 10 (7) 5 (4) 4 (5) 0.690
Cancer charity (any) 44 (13) 14 (9) 22 (19) 8 (10) 0.055
Online peer support 16 (5) 6 (4) 6 (5) 4 (5) 0.880
Abbreviations: * F2F: face to face. ** HCP: healthcare professional.
2.7. Health-Related Quality of Life (HRQoL)
Figure 2 compares the HRQoL of participants according to the self-reported treatment intent
and the UK normative population values (non-pandemic) [22]. Significant differences according to
treatment intent were observed in the domains of physical functioning (p = 0.0001), role functioning
(p = 0.001), social functioning (p = 0.004), global health/QoL (p = 0.0001) and insomnia (p = 0.033).
For these domains, patients treated with palliative intent had worse functioning, worse global HRQoL
and higher insomnia scores than patients treated with curative intent. Patients who did not know the
intent of their treatment had scores that fell between the curative group and palliative group for all
of these domains except insomnia; these patients had the highest levels of insomnia. Cognitive and
emotional functioning scores were also lower in this group, however, differences in these domains
were not statistically significant. Patients treated with curative intent appeared to have higher physical,
emotional and cognitive functioning, higher global HRQoL scores and lower insomnia scores, than the
UK normative population during “non-pandemic” times.
2.8. Multivariate Analysis: Cancer Worry and COVID-19 Worry
After controlling for potential covariates, higher worry about the potential impact of COVID-19
on personal health was associated with significantly higher worry about sarcoma, irrespective of
treatment intent (p = 0.0001) (Table 4). In patients treated with curative intent, higher COVID-19 worry
was associated with lower resilient coping (p = 0.012). For patients who were unsure of their treatment
intent (unknown intent), higher COVID-19 worry was associated with lower global HRQoL (p = 0.012).
Higher level of worry about sarcoma was associated with significantly lower emotional functioning
across all groups. In patients treated with palliative intent, higher level of worry about sarcoma was
associated with the pandemic having an impact on social life/activities (p = 0.039). Patients having
palliative treatment and who were more worried about sarcoma were less likely to have a telemedicine
appointment (p = 0.001). For patients who did not know their treatment intent, higher level of worry
about sarcoma was associated with being on treatment (p = 0.038).
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Figure 2. Health-related quality of life according to treatment intent. p-values: * p ≤ 0.05, ** p ≤ 0.001.
Table 4. Multivariate linear regression: factors associated with sarcoma worry and COVID-19 worry.
Worry about COVID-19 on Health Worry about Sarcoma
Patient Factors CurativeIntent
Palliative
Intent
Unknown
Intent
Curative
Intent
Palliative
Intent
Unknown
Intent
Age (continuous) - - - - β = −0.026p = 0.782 -
Ethnicity
(Caucasian vs. other) - -
β = 0.102
p = 0.233 - - -
Loneliness (continuous) β = 0.077p = 0.393 - -
β = −0.110
p = 0.242 - -
Resilient coping
(continuous)
β = −0.206
p = 0.012 - -
β = −0.060
p = 0.475 - -
Comorbidities (Yes/No) - - - - β = −0.127p = 0.160 -
Care Factors
On treatment (Yes/No) β = 0.056p = 0.475 -
β = 0.175
p = 0.062
β = 0.116
p = 0.183 -
β = 0.221
p = 0.038
Telemedicine (Yes/No) - - - β = −0.101p = 0.232
β = −0.282
p = 0.001
β = −0.069
p = 0.525
Appointment
postponed (Yes/No) - - -
β = −0.057
p = 0.494 - -
Treatment postponed
(Yes/No) - - - -
β = 0.094
p = 0.260 -
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Table 4. Cont.
Worry about COVID-19 on Health Worry about Sarcoma
Patient Factors CurativeIntent
Palliative
Intent
Unknown
Intent
Curative
Intent
Palliative
Intent
Unknown
Intent
Impact of Pandemic
Financial impact
(Yes/No) - -
β = 0.037
p = 0.690 -
β = 0.064
p = 0.438 -
Family impact (Yes/No) - β = 0.090p = 0.300
β = 0.036
p = 0.696 -
β = 0.041
p = 0.716
Emotional impact
(Yes/No)
β = 0.173
p = 0.056
β = 0.175
p = 0.071
β = 0.048
p = 0.620 -
β = −0.060
p = 0.541
β = 0.180
p = 0.117
Social life impact
(Yes/No) -
β = 0.119
p = 0.173 -
β = 0.171
p = 0.039 -
HRQoL
Sarcoma worry
(continuous)
β = 0.340
p = 0.0001
β = 0.464
p = 0.0001
β = 0.582
p = 0.0001 - - -
Physical functioning
(continuous)
β = −0.187
p = 0.122
β = −0.011
p = 0.928
β = −0.009
p = 0.941
β = −0.051
p = 0.686
β = −0.037
p = 0.758
β = 0.114
p = 0.424
Emotional functioning
(continuous)
β = 0.054
p = 0.661
β = 0.011
p = 0.923
β = 0.105
p = 0.427
β = −0.409
p = 0.0001
β = −0.410
p = 0.0001
β = −0.572
p = 0.0001
Role functioning
(continuous)
β = 0.065
p = 0.547
β = −0.058
p = 0.644
β = 0.013
p = 0.915
β = −0.103
p = 0.370
β = 0.101
p = 0.423
β = −0.101
p = 0.510
Cognitive functioning
(continuous)
β = 0.030
p = 0.778
β = −0.109
p = 0.283
β = 0.136
p = 0.218
β = 0.215
p = 0.061 -
β = 0.046
p = 0.735
Social functioning
(continuous)
β = −0.129
p = 0.218
β = 0.012
p = 0.925
β = 0.067
p = 0.571
β = −0.098
p = 0.364
β = −0.201
p = 0.127
β = −0.187
p = 0.192
Global HRQoL
(continuous)
β = 0.064
p = 0.540
β = 0.108
p = 0.347
β = −0.285
p = 0.012
β = 0.032
p = 0.775
β = −0.051
p = 0.662
β = 0.117
p = 0.404
Insomnia (continuous) β = −0.042p = 0.639 -
β = 0.238
p = 0.053
β = 0.088
p = 0.353 -
β = −0.166
p = 0.259
3. Discussion
To our knowledge this is the first study to assess care experiences and HRQoL among adult
patients with sarcomas during the COVID-19 pandemic. A substantial proportion of follow-up
appointments and scans were postponed, and many patients were monitored remotely through
telemedicine (telephone or video consultations). These modifications were generally perceived to
be good decisions and most patients felt able to contact their healthcare professionals as normal.
Treatment was not commonly postponed; patients undergoing palliative treatment were less certain
whether this was a good or bad decision. Patients with high levels of worry about cancer were the most
worried about the potential impact of COVID-19 on their health and had lower emotional functioning,
irrespective of treatment intent. Low resilient coping scores were also related to higher COVID-19 worry
in curative patients. Early identification of patients with low resilience and cancer-related worry may
facilitate timely psychological support across the disease trajectory. Patients who reported unknown
treatment intent experienced high levels of worry about COVID-19 and sarcoma, lower emotional
functioning, and had high levels of insomnia. Treatment goals should be discussed at appropriate
time points taking into account individual preferences for information provision, such as disclosure
of prognosis.
Consistent with the known risks of COVID-19 in people with cancer, half of patients perceived
their own risk of COVID-19 to be greater than the general population. Patients also reported wide
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ranging impacts of the pandemic on their emotional wellbeing, finances, employment, family and
social life, consistent with trends seen in the general population [23].
Consistent with national guidelines for delivery of cancer care during the COVID-19 pandemic,
many patients were monitored remotely through telemedicine [17]. Face to face contact was also
significantly reduced through postponement of follow-up appointments and scans where appropriate.
Mehta et al. recently reported that interaction with healthcare environments was a prominent source
of exposure to SARS-CoV-2 for cancer patients, emphasising the importance of avoiding non-essential
visits to the hospital [14].
Treatment interruptions (postponement or cessation) were uncommon for patients in our study,
however, these decisions were understandably perceived with uncertainty among some patients
undergoing palliative treatment. An international survey of 149 physicians across five continents also
reported reductions in all treatments including surgery, radiotherapy and chemotherapy for patients
with musculoskeletal tumours [24]. Notably, palliative chemotherapy and radiotherapy were stopped
or delayed in 20% and 17% of cases, respectively [24]. While the authors concluded that significant
harm (pain, morbidity, loss of function) could be caused by delays to care for musculoskeletal tumours
such as sarcomas, the true impact in terms of reduction in COVID-19 risk compared to cancer outcome
is unknown [24]. Importantly, in our study, the vast majority of patients themselves reported the
decision to delay care within the pandemic was a good decision. Follow-up studies are necessary to
evaluate longer-term clinical outcomes and patient reported outcomes as it is conceivable that patient
symptoms, HRQoL and prognosis may be affected.
Given the rarity and complexity of sarcomas, it is recommended that all patients are managed in a
reference centre for sarcomas and/or within reference networks with multidisciplinary expertise [25,26].
However, as shown in this study, patients often live a long distance from reference centres.
Rapid implementation of telemedicine during the COVID-19 pandemic has given us the opportunity
to evaluate the acceptability of remote monitoring, showing that the majority of patients would prefer
the incorporation of telemedicine in follow-up. Given the increasing pressures on global healthcare
systems, including the National Health Service (NHS) in the UK, telemedicine may be an effective
way to manage selected patients [27]. Preference for face to face appointments was associated with
lower resilient coping and was more common in patients who did not know their treatment intent.
These groups of patients may require more reassurance through face to face appointments. Methods
to identify patient and provider preferences are needed to successfully implement telemedicine in
routine care.
The prevalence of perceived social isolation in cancer patients is poorly defined, however, previous
research and reports suggest it may be experienced by around a quarter of individuals [28]. Social
isolation was much higher in our study, with almost half of the participants reporting that they felt
isolated. The increased level of perceived isolation is likely a direct result of the COVID-19 pandemic
self-isolation recommended by the UK government. A number of researchers have highlighted the
negative health effects of social isolation as an unintended consequence of social distancing and the
need for mitigation efforts [29–32]. This is particularly important for individuals with cancer where
social isolation is associated with a number of clinical and psychosocial outcomes including mortality
and HRQoL impairments [33,34].
In our study, 41% of patients reported that their emotional wellbeing was impacted by the
COVID-19 pandemic. Interestingly, EORTC-QLQ-C30 emotional functioning scores were slightly
better in patients with sarcoma (curative or palliative intent groups) compared to a normative UK
population during a “non-pandemic” period [22]. Although these data are not directly comparable,
adaptive coping strategies developed during cancer diagnosis and treatment may enable patients to
cope with other adverse situations [35]. Patients that did not know the aim of the treatment had lower
emotional functioning, higher worry about COVID-19 and higher insomnia scores. Although these
findings could be attributed to uncertainty about the treatment goals, these patients may be a distinct
group who require more support.
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Patients who reported palliative intent of treatment/sarcoma management generally had worse
HRQoL scores than those treated with curative intent. Unfortunately, EORTC-QLQ-C30 reference
values for patients with sarcoma are not available for comparison and we propose repeating HRQoL
analysis after the pandemic to determine whether observed trends remain and to evaluate the magnitude
of those differences.
There is evidence of widespread anxiety, distress and deterioration in mental health in the general
population during the COVID-19 pandemic, and a number of studies have evaluated the impact on
cancer patients [36]. A Dutch study compared wellbeing in >4000 cancer patients with a matched
norm-population without cancer [37]. Quality of life scores were similar; however, cancer patients
were more worried about COVID-19 infection while norm-participants were significantly more likely
to report depression and loneliness compared to cancer patients [37]. In another survey of breast
cancer patients, around half had symptoms of anxiety, depression and insomnia, while 83% showed
symptoms of distress [38]. Frey et al. evaluated the impact of COVID-19 in patients with ovarian
cancer [39]. The majority reported significant cancer worry, half had borderline or abnormal anxiety,
and a quarter had borderline or abnormal depression [39]. Romito et al. evaluated psychological
distress in lymphoma patients and found anxiety and depressive symptoms in around one-third of
patients during the pandemic [40]. Using a self-developed COVID-19 questionnaire, Falcone et al.
found mean COVID-19 concern of 8/12 (interquartile range {IQR} 5–9) in thyroid cancer patients,
which was inversely correlated with EORTC-QLQ-C30 emotional functioning scores [41]. Although
these studies used a variety of questionnaires (validated or developed by researchers) and included
patients with heterogeneous socio-demographic characteristics, different cancer types and disease
stages, they further highlight the unmet need for psychological support in cancer patients during the
COVID-19 pandemic and across the disease trajectory [42].
3.1. Implications for Care
The COVID-19 pandemic has been a period of great uncertainty. While vaccines are not available
and “normality” may be many months away, we need to consider how we can identify and support
patients who may be more vulnerable during the pandemic and at other stressful time points during
their disease trajectory. Worry about COVID-19 was significantly associated with overall cancer-related
worry, irrespective of treatment intent. Higher cancer-related worry was also associated with lower
emotional functioning across all treatment intent groups. In clinical practice, screening patients
for cancer-related worry may identify patients who require psychological support, both during the
pandemic and beyond. Brief screening methods, such as the distress thermometer (patients rate
their distress on a scale from 0 to 10), may be useful to recognise patients who may benefit from
psychosocial support and enable tailored psychosocial interventions early in their cancer treatment [43].
More detailed assessments such as the Hospital and Anxiety Depression Scale (HADS) and the
Brief Symptom Inventory (BSI), may also be suitable for assessing psychological concerns across the
disease trajectory [44]. A number of studies have supported the efficacy of psychosocial interventions,
which can be provided on an individual, family or group level. Well-established approaches for
cancer patients include cognitive–behavioural, existential, and psychodynamic therapies [44]. Referral
to specialist psycho-oncology services should be part of the multidisciplinary approach to cancer
patient management.
We also found that lower resilient coping score was associated with higher COVID-19 worry in
patients treated with curative intent. Patients who had low resilient coping scores were significantly
more likely to indicate that they would prefer face to face appointments only; demonstrating that
these patients may find personal interaction more reassuring. Resilience and coping are influenced by
biological, personal and social factors, and there is substantial evidence that resilience is related to
higher cognitive functioning and quality of life, and lower levels of anxiety [45]. We used the four-item
Brief Resilient Coping Scale (BRCS) to assess resilient coping in our study. The BRCS has shown
internal consistency and validity across several different diseases and populations, and it is short and
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easy to administer [46]. As such, this tool could be used to screen patients in clinical practice who may
benefit from additional support during adverse periods; not only the COVID-19 pandemic, but other
challenging clinical situations such as recurrence or progression of disease. A number of tailored
interventions are available to promote resilience, improve adaptive coping strategies, alleviate distress
and promote better HRQoL [47]. For example, the “Promoting Resilience in Stress Management
(PRISM)” intervention, focuses on skills to manage stress through cognitive reframing, setting goals
and meaning making, and has shown beneficial psychosocial outcomes in adolescents and young
adults with cancer [48].
The group of patients who did not know their treatment intent (unknown intent; n = 77) had high
worry about COVID-19 and sarcoma, insomnia and were more likely to prefer face to face appointments.
Evidence indicates that treatment goals and prognosis are often not discussed due to worry that
this information will take away hope or make patients depressed, or because these discussions are
emotionally upsetting for clinicians themselves [49]. However, hope can be maintained through setting
realistic goals, even in the setting of incurable disease [50]. Early discussions about treatment goals in
the context of patient values may help to guide management decisions including timely advance care
planning. Uncertainty about treatment intent in sarcoma patients requires further study.
Loneliness was associated with living alone and not having a partner. Social isolation during
self-isolation when living alone is complex and these patients may be at higher risk for adverse
psychosocial outcomes [29]. Loneliness was also more common among adolescents and young adults
(aged 16–39 years) and middle-aged patients (aged 40–64 years). Previous studies have described
loneliness and isolation among adolescents and young adults with cancer, resulting from disruption
to normal developmental challenges and feeling “different” to peers [51]. Interventions that have
shown promise in reducing loneliness include those focused on enhancing social skills, providing
social support, facilitating opportunities for social contact and addressing maladaptive social cognition;
the latter appears to be the most effective strategy [52]. The challenge is to introduce safe interventions
that can support vulnerable patients and adhere to national guidelines on social distancing. Technology
has been vitally important for the delivery of care during this pandemic and support could be provided
through existing digital health innovations [53]. Others have tested innovative methods during
the pandemic, such as a Whatsapp messaging system for resolving queries during the COVID-19
pandemic [54]. Alternative approaches must be considered for people without access to the internet.
Signposting patients to accurate information will also be important, including advice about boosting
wellbeing through physical activity and nutritional support.
3.2. Limitations
Participants in this survey were mostly White and well-educated. It would be interesting to assess
the views of patients from a wider range of educational backgrounds, and also evaluate the experiences
of patients from Black, Asian, and minority ethnic backgrounds; a group at particularly high risk of
complications due to COVID-19. Translation of surveys and the use of other qualitative methods,
such as interviews, could also be considered for future studies. Patients self-reported their treatment
intent; however, previous studies have shown significant discordance between patient expectations of
treatment intent [55]. As the survey was anonymous, we did not link survey responses with clinical
data and therefore verification of treatment intent was not possible. The UK has a publicly-funded
National Health Service (NHS), and therefore these data may not be generalizable to other countries
where socioeconomic and demographic factors influence access to healthcare; such disparities may be
further exaggerated during the pandemic due to variability in financial support offered by governments,
public health guidance and cancer care infrastructure.
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4. Materials and Methods
This study was a cross-sectional survey assessing the experiences of sarcoma patients at two of
the largest specialist sarcoma centres in Europe, the Royal Marsden NHS Foundation Trust (RMH) and
the University College London Hospitals NHS Foundation Trust (UCLH, London Sarcoma Service).
4.1. Participants
We identified patients aged ≥16 years with a diagnosis of sarcoma (soft tissue sarcomas,
bone sarcomas and gastrointestinal stromal tumours (GIST)), who had a planned outpatient
appointment between 23 March and 23 May 2020 in the Medical Oncology and Radiation Oncology
departments of the Sarcoma Units at RMH and UCLH. Patients with benign tumours, including
desmoid fibromatosis, that were unable to communicate in English or too unwell, were not eligible.
Eligible patients at RMH consented by phone to receive the anonymous survey (online or
paper version). Eligible patients at UCLH were invited by phone or sent an email with the survey
details. The survey was administered through SurveyMonkey; whose security has been established in
accordance with international standards [56]. Data collection was completed 30 May 2020.
4.2. Measures
The survey for this study was designed by sarcoma clinicians, an epidemiology and HRQoL
expert (O.H.), a patient advocate (R.W.) and the patient and public involvement panel (PPI) of the RMH
(Appendix B). The survey included a combination of validated questionnaires and items developed
for this study. Questions developed for this survey included socio-demographic items, sarcoma
management items, worry about COVID-19, psychosocial impact of the COVID-19 pandemic, and care
experiences during the pandemic. Further details and preliminary results of the telemedicine section
have been published elsewhere [27].
HRQoL was assessed using the European Organization for the Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC-QLQ-C30) functioning scales (physical, cognitive, social, role and
emotional functioning), global health status/QoL items, and the insomnia item. HRQoL were analysed
using EORTC scoring guidelines, all of the scales and single-item measures range in score from 0 to
100 [57]. High scores on the scales and global HRQoL items represent high functioning or HRQoL.
A high score on the insomnia item represents worse insomnia.
The UCLA (University of California, Los Angeles) abbreviated Loneliness Scale was used to assess
loneliness [58]. The sum of responses to the three items of this scale indicates whether respondents
are lonely (scores 6–9) or not lonely (scores 3–5). The ability to cope with stress was assessed using
the Brief Resilient Coping Scale (BRCS) [46]. Summed scores correspond to “low resilient copers”
(4–13 points), “medium resilient copers” (14–16) and “high resilient copers” (17–20) [45].
4.3. Statistical Analysis
SPSS statistics version 25 was used for the analysis. Missing responses were not included, and only
available data were analysed. The online survey was programmed to ensure that all EORTC-QLQ-C30
questions were answered before responses could be submitted. Descriptive statistics were used to
summarise results; frequencies and percentages for categorical items, mean and standard deviation
(SD) for continuous items.
We anticipated that the COVID-19 pandemic would have a different impact on patients undergoing
treatment with palliative intent compared to curative intent, and therefore stratified responses according
to self-reported treatment intent (curative vs. palliative). In order to assess overall worry about
sarcoma and COVID-19, we further stratified patients receiving active treatment versus those not
receiving active treatment. We also included the group of patients who did not know the aim of their
treatment or management as the “unknown intent” group. As EORTC-QLQ-C30 sarcoma patient
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reference values are not available, we included UK normative population values for comparison with
HRQoL data (non-pandemic) [22].
We used Chi-squared tests to evaluate differences between categorical variables (Fisher’s exact test
where cell values were ≤5). ANOVA was used to assess differences in the means between treatment
groups (curative, palliative or unknown intent), including age, sarcoma worry, COVID-19 worry
and HRQoL scores. We used multivariate linear regression to assess associations between patient
characteristics, care modifications, psychosocial impact of pandemic, HRQoL domains, worry about
COVID-19 and worry about sarcoma in each treatment group (curative/palliative/unknown intent)
separately. Factors significantly associated with the independent and dependent variable in univariate
analysis at the p ≤ 0.100 level were included in the models. p-values of ≤0.05 were considered
statistically significant.
4.4. Ethical approval
Ethical approval was obtained at the RMH from the Committee for Clinical Review (SE939).
Ethical approval was not required at UCLH for this survey. Anonymous survey responses from patients
recruited at RMH and UCLH were combined for the final analysis. All participants gave informed
consent prior to completing the survey. All data were handled in accordance with the Declaration
of Helsinki.
5. Conclusions
Postponement of care and the use of telemedicine to replace face to face appointments were
generally perceived positively, however, the longer-term clinical consequences are not yet known.
Worry about potential impact of COVID-19 on personal health was moderately high and was strongly
related to the level of worry about cancer and resilient coping. Emotional functioning was significantly
lower in patients with high cancer-related worry, irrespective of treatment intent. Patients with high
cancer-related worry or low resilience may benefit from tailored psychological support across their
disease trajectory, in order to promote coping during other adverse (clinical) situations. Patients who
were uncertain about their treatment intent appeared to be a distinct group with high COVID-19 worry,
high insomnia and low emotional functioning. Discussions about treatment goals, which consider
information preferences and beliefs, may reduce uncertainty and improve HRQoL in these patients.
In view of global changes to the delivery of cancer care during the COVID-19 pandemic, our findings
are of relevance to the wider cancer population. Further studies are needed to assess the longer-term
impact of the pandemic on HRQoL in patients with cancer.
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Appendix A. Patient Recruitment
Figure A1. Flow chart of patient recruitment.
Appendix B. Questionnaire
Sarcoma Patient Experience during COVID-19 Pandemic
Questionnaire
Instructions:
Thank you for volunteering to take part in this survey to help us to understand more about the
experiences of patients with sarcoma during the coronavirus (COVID-19) pandemic. Please attempt
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to answer all of the questions. Please choose the answer option that is most applicable to your own
situation. In this survey we will use the term ‘COVID-19’ to refer to the disease causing the current
pandemic and refer to the ‘COVID-19 pandemic’ where appropriate.
Section 1: About you
1. How old are you?
. . . . . . . years
2. What is your gender?
Male
Female
Other, please specify__________________________
3. What is your ethnicity?
European/Caucasian
Asian
Black
Mixed
Other, please specify____________________________
4. What is your current living situation? (Please check all that apply)
I live alone
I live with my spouse/partner
I live with children in the home
I live with friend(s) or roommate(s) who are not related to me (e.g., students or lodgers)
I live with my parent(s)
Other, please specify____________________________
5. What is your marital status?
Married/in a relationship
Divorced
Widowed
Single
6. What is your highest level of education?
None/Primary school
Secondary school
College/diploma/vocational qualification
University/postgraduate degree
7. Do you have any of the following medical conditions? (please tick all that apply)
Chronic Obstructive Pulmonary Disease (COPD)
Hypertension (high blood pressure)
Diabetes
Coronary artery disease/heart disease (e.g., previous heart attack)
Obesity
None of the above
8. How long is your usual journey time from your home to the Royal Marsden Hospital?
Less than 1 h journey time
More than 1 h journey time
9. How do you usually travel to the Royal Marsden Hospital? (please tick all that apply)
I walk
Bus
Train
Underground
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Car
Other, please specify____________________________
Section 2: COVID-19
1. On a scale of 1 to 10, please rate your current level of worry about the impact of COVID-19 on
your health. (1—not worried at all, 10—extremely worried).
2. Do you think you are at higher risk of contracting COVID-19 than others in the population:
Yes, higher risk
Equal, same risk
No, lower risk
Don’t know
3. Do you think you have had COVID-19?
Yes, confirmed with swab (test)
Yes, I think I had symptoms of the COVID-19, but have not had a test to confirm
Yes, I think I had symptoms of COVID-19, but I had a negative test
No, I have not had symptoms of COVID-19
I don’t know
4. Has the COVID-19 pandemic had an impact on any of the following? (please tick all that apply)
Employment
Financial situation
Family life
Emotional wellbeing
Social life/activities
Other, please specify____________________________
5. In the next 12 months, if you developed a life threatening respiratory disease (due to COVID-19
or other cause), do you think you would accept treatment with a ventilator (a machine to breathe
for you)?
Yes
No
I don’t know.
Section 3: Sarcoma
1. On a scale of 1 to 10, please rate your current level of worry about your sarcoma? (1—not worried
at all, 10—extremely worried)
2. Are you currently having treatment for sarcoma?
Yes, intravenous (through a vein) anticancer treatment given at the hospital
Yes, oral (tablets) anticancer treatments
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Yes, radiotherapy
Yes, other treatment for sarcoma (please specify)
No, I am not receiving treatment.
I don’t know.
3. Are you currently taking part in a clinical trial (i.e., research study)?
Yes, I am currently receiving treatment as part of a clinical trial
No, I was taking part in a trial but my participation was paused due to COVID-19 pandemic
No, I was taking part in a clinical trial but my participation was stopped due to
COVID-19 pandemic
No, I was being considered for a clinical trial but this was put on hold due to COVID-19 pandemic
No, I am not taking part in a clinical trial.
4. What is the aim of your current treatment or management plan (including surveillance or
monitoring with scans)?
Curative (cure of disease) or I have no evidence of sarcoma
Palliative (control of disease)
I do not know.
5. Over the last year, what was the usual frequency of your follow-up appointments with the
sarcoma team?
Intervals of less than three months (e.g., every few weeks)
Three or four month interval
Six month intervals
Annual
Other, please specify____________________________
Section 4: Telemedicine
1. Have you had an appointment with the sarcoma team at the Royal Marsden Hospital since 23
March 2020?
Yes, I have had a face to face appointment at the Royal Marsden Hospital.
Yes, I have had a telephone appointment with a doctor from the Royal Marsden Hospital.
Yes, other e.g., video consultation
No, I have not had an appointment
I don’t know
2. If you have had a face to face appointment with a doctor in the hospital since 23 March 2020,
how satisfied were you with the consultation? (Please select a number on the scale from 1–10:
1 = not satisfied at all and 10 = extremely satisfied). If you have not had a face to face appointment
during this period, please tick not applicable.
Not applicable
3. If you have had a telephone appointment with a doctor since 23 March 2020, how satisfied where
you with the consultation? (Please select a number on the scale from 1–10: 1 = not satisfied at all
and 10 = extremely satisfied). If you have not had a telephone appointment during this period,
please tick not applicable.
Not applicable
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4. If you had a video appointment (e.g., Zoom/Skype) with a doctor since 23 March 2020, how satisfied
where you with the consultation? (Please select a number on the scale from 1–10: 1 = not satisfied
at all and 10 = extremely satisfied). If you have not had a video appointment during this period,
please tick not applicable.
Not applicable
5. I had previously met the doctor who performed my telemedicine appointment.
Yes
No
I don’t know
Not applicable
6. If you had a choice for your future routine appointments:
(a) Which type of consultation would you prefer? (please choose one option) Face to face
appointments only
Mostly face to face appointments, occasional telemedicine
Mostly telemedicine appointments, occasional face to face appointments
Only telemedicine appointments
I don’t know.
(b) What are the main reasons that you chose this option? (please select all that apply)
Reduced time travelling to the hospital
Reduced cost of travelling to the hospital
Reduced waiting in the hospital
I would find it more reassuring
I think my treatment plan would be clearer
I think it is more convenient
Other, please specify____________________________
7. If telemedicine (phone or video) was an option for patient care at the Royal Marsden Hospital
moving forward, I would prefer using the following method: (please select one option)
Telephone
Video call (such as Zoom, or Skype)
8. I would not wish to hear the following information by a telemedicine (phone or video) appointment
(please select all that apply)
Any results of imaging tests (CT scan or MRI results)
Bad news from imaging tests (i.e., growth of cancer on CT or MRI test, new area of cancer seen on
imaging test)
Blood test results
Results from a team discussion regarding my care (for example, whether the team recommended
to continue with my current treatment or suggested that I need to see a surgeon to manage
my cancer)
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9. Do you think having a specialist nurse in sarcoma participate in the telemedicine (phone or video)
appointment would be useful?
Always
Sometimes—for example when the doctor is telling me bad news (like CT scan showing cancer is
growing or new areas of cancer)
Sometimes—I would like the option of asking for a nurse to be present during my
telemedicine appointment
Never
I don’t know
Section 5: Experiences of Care
1. Have your follow-up appointments been postponed due to the COVID-19 pandemic?
No, my follow-up has not changed
Yes, postponed for up to three months.
Yes, postponed for more than three months
I don’t know
2. If your follow-up appointments have been postponed, what are your views on that decision?
I think it was a good decision
I think it was a bad decision
I am not sure whether it was a good or bad decision.
Not applicable, my appointments have not been changed.
3. Have your scans been postponed due to due to the COVID-19 pandemic?
No, my routine scans have not changed
Yes, postponed for up to three months.
Yes, postponed for more than three months
Not applicable, I do not have scans
I don’t know
4. If your scanshave been postponed, what are your views on that decision?
I think it was a good decision
I think it was a bad decision
I am not sure whether it was a good or bad decision.
Not applicable (my routine scans have not been changed, or I do not have scans)
5. Has your treatment been postponed or discontinued due to the COVID-19 pandemic?
No, my treatment has continued as normal
Yes, postponed for up to three months
Yes, postponed for more than three months
Yes, my current treatment has been discontinued
Not applicable, I am not on treatment
I don’t know
6. If your treatment has been postponed or discontinued, what are your views on that decision?
I think it was a good decision
I think it was a bad decision
I am not sure whether it was a good or bad decision.
Not applicable, my treatment has not been postponed
Not applicable, I am not on treatment.
7. Are you concerned about the quality of your care during the COVID-19 pandemic
My care has not been affected
The pandemic has had a negative impact on my care
The pandemic has had a positive impact on my care
I don’t know
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8. Do you feel informed about the plan for your follow-up (and treatment if applicable)?
Yes, very well informed
Yes, informed
I received very little information
Not informed at all
Section 5: Health-related Quality of life
1. We are interested in some things about you and your health. Please answer all of the questions
yourself by choosing the option that best applies to you. There are no “right” or “wrong” answers.
Not at All A Little Quite a Bit Very Much
Do you have any trouble doing strenuous activities like
carrying a heavy shopping bag or a suitcase?
Do you have any trouble taking a long walk?
Do you have any trouble taking a short walk outside of
the house?
Do you need to stay in bed or a chair during the day?
Do you need help with eating, dressing, washing yourself
or using the toilet?
During the past week:
Were you limited in doing either your work or other
daily activities?
Were you limited in pursuing your hobbies or other
leisure time activities?
Have you had trouble sleeping?
Have you had difficulty in concentrating on things,
like reading a newspaper or watching television?
Did you feel tense?
Did you worry?
Did you feel irritable?
Did you feel depressed?
Have you had difficulty remembering things?
Has your physical condition or medical treatment
interfered with your family life?
Has your physical condition or medical treatment
interfered with your social activities?
For the following two questions, please choose the number between 1 and 7 that best applies
to you.
2. How would you rate your overall health during the past week?
3. How would you rate your overall quality of life during the past week?
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Section 6: Support and coping
The next three questions are about how you feel about different aspects of your life. For each one,
indicate how often you have felt that way over the past week.
1. How often do you feel that you lack companionship?
Hardly ever
Some of the time
Often
2. How often do you feel left out?
Hardly ever
Some of the time
Often
3. How often do you feel isolated from others?
Hardly ever
Some of the time
Often
4. Who would you choose to contact for any problems related to your sarcoma, or questions about
your cancer care during the COVID-19 pandemic? (please tick all that apply)
Sarcoma clinical nurse specialist
Royal Marsden Hospital helpline
General practitioner (GP)
Sarcoma charity (e.g., Sarcoma UK, BCRT)
Other cancer charity (e.g., Macmillan, Cancer Research UK)
Online peer support groups
NHS helpline (111)
Other, please specify____________________________
5. Do you feel comfortable contacting your healthcare providers (GP or sarcoma team) during the
COVID-19 pandemic?
I feel able to contact my healthcare providers as normal
I am worried about availability of healthcare providers
I would try not to contact healthcare providers unless absolutely essential
I don’t know
6. Consider how well the following statements describe your usual behaviour and actions:
(1) Does not
describe me at all
(2) Does not
describe me
(3) Neutral
(4) Describes
me
(5) Describes
me very well.
I look for creative ways to alter
difficult situations
Regardless of what happens to
me, I believe I can control my
reaction to it.
I believe I can grow in positive
ways by dealing with difficult
situations
I actively look for ways to replace
the losses I encounter in life.
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Please use the space below to add any further comments:
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